Otis W Brawley bought $20k of LYEL
director at Lyell Immunopharma, Inc.. 35,640 shares at an average of $0.56, traded Mar 31, 2025, filed Apr 2, 2025.
Score components
- +15RoleDirector
- 0Trade size$20k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context66% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-009604, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | POpen-market purchase Common Stock | +35,640 | $0.56 | $20k | 35,640 | Apr 2, 2025 |
Related signals
Other insiders at Lyell Immunopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | LYELsell Lyell Immunopharma, Inc. | David Shook Chief Medical Officer | $6,350 500 shares | -2% | |
| 58Moderate | Lyell Immunopharma, Inc. | ARCH Venture Partners IX, LLC owner | $12M 488,090 shares | +52% | |
| 58Moderate | Lyell Immunopharma, Inc. | ARCH Venture Fund XIII, L.P. owner | $12M 488,090 shares | +52% | |
| 40Moderate | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $29k 1,236 shares | -6% | |
| 36Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $39k 1,671 shares | -9% | |
| 51Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $174k 7,455 shares | -9% | |
| 30Weak | Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $5,872 254 shares | -2% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $2,520 109 shares | -1% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $3,399 147 shares | -1% | |
| 40Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $10k 438 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.